SNCA and Parkinson disease: Even though there are other therapeutic approaches under development and continuous clinical trials ongoing, such as gene therapies, immunotherapies targeting α-synuclein, or stem cell-based treatments, levodopa is at present the most commonly used treatment for PD patients as it significantly reduces motor symptoms [93,94].